Figure 2.

Axitinib and AB1010 inhibited cell proliferation in TCC cells in a dose-dependent manner. (A, B) h-UM-UC-3, T24, and 5637, and (C, D) K9TCC#1Lillie and K9TCC#5Lilly cells were treated with axitinib and AB1010 at a dose of 0, 1, 5, and 10 μM for 48 hours and cell viability was assessed by MTS assay. Both the tested RTKIs inhibited cell viability of TCC cells in a dose-dependent manner. Relative cell growth rates were normalized to the controls. Values represent mean ± SE of four replicates from three independent experiments; paired Student’s t-test, *p<0.05, and ***p<0.001. Symbols denote p-value for each cell line: *(UM-UC-3), ^Δ(T24), ^&(5637), ^‡(Lillie), and ⁺(Lilly) ^&&&p<0.001, ^ΔΔΔp<0.001, ^‡‡‡p<0.001, ⁺⁺⁺p<0.001, ⁺p<0.05, ^‡p<0.05, and ^Δp<0.05.

Abbreviations: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt; TCC, transitional cell carcinoma; RTKI, receptor tyrosine kinase inhibitor.